Page 100 - Human Use News Today

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A

16.12.2022 - If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) - uniQure N.V. (NASDAQ: QURE), a leading gene therapy ... Seite 1

If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in...

The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222

        CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi (SNY) announced Friday that the European Medicines Agencys Committ...

16.12.2022 -         CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and ... Seite 1

Investegate announcements from Moderna Inc, EMA Committee for Medicinal Products for Human Use

MARBURG, GERMANY Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for hemophilia B to patients in Europe.

V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated